MX2021005313A - Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico. - Google Patents

Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico.

Info

Publication number
MX2021005313A
MX2021005313A MX2021005313A MX2021005313A MX2021005313A MX 2021005313 A MX2021005313 A MX 2021005313A MX 2021005313 A MX2021005313 A MX 2021005313A MX 2021005313 A MX2021005313 A MX 2021005313A MX 2021005313 A MX2021005313 A MX 2021005313A
Authority
MX
Mexico
Prior art keywords
domain
nucleic acid
mini
core proteins
nucleosome core
Prior art date
Application number
MX2021005313A
Other languages
English (en)
Inventor
Adarsha Koirala
Original Assignee
Summation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summation Bio Inc filed Critical Summation Bio Inc
Publication of MX2021005313A publication Critical patent/MX2021005313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona composiciones y métodos que se relacionan con proteínas de núcleo de mininucleosoma y/o la administración de ácidos nucleicos. En particular, la presente descripción incluye, entre otras cosas, vehículos proteicos no virales para la administración de ácidos nucleicos. En varias modalidades, los vehículos proteicos 5 no virales proporcionados en la presente incluyen (a) un dominio de unión a ácido nucleico; (b) un dominio de direccionamiento; y, opcionalmente, (c) un dominio de liberación de ácido nucleico, dominio de estabilidad y/o dominio de oligomerización, y/o un dominio enlazador.
MX2021005313A 2018-11-08 2019-11-06 Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico. MX2021005313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862757683P 2018-11-08 2018-11-08
PCT/US2019/060119 WO2020097235A1 (en) 2018-11-08 2019-11-06 Mini-nucleosome core proteins and use in nucleic acid delivery

Publications (1)

Publication Number Publication Date
MX2021005313A true MX2021005313A (es) 2021-10-13

Family

ID=70611091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005313A MX2021005313A (es) 2018-11-08 2019-11-06 Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico.

Country Status (12)

Country Link
US (1) US20210395303A1 (es)
EP (1) EP3877526A4 (es)
JP (2) JP2022512977A (es)
KR (1) KR20210108952A (es)
CN (1) CN113423834A (es)
AU (1) AU2019376641A1 (es)
BR (1) BR112021008832A2 (es)
CA (1) CA3118146A1 (es)
IL (1) IL282982A (es)
MX (1) MX2021005313A (es)
SG (1) SG11202104354TA (es)
WO (1) WO2020097235A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102470059B1 (ko) * 2018-05-18 2022-11-22 에프. 호프만-라 로슈 아게 큰 핵산의 표적화된 세포내 전달
IL297250A (en) * 2020-04-13 2022-12-01 Summation Bio Inc Modified mininucleosome core proteins and use in nucleic acid delivery
CA3226457A1 (en) * 2021-07-30 2023-02-02 Amy WALKER Nanoparticles and peptides for the delivery of cargos to muscle cells
EP4124345A1 (en) * 2021-07-30 2023-02-01 4basebio UK Ltd Nanoparticles for muscle delivery
WO2023014724A2 (en) * 2021-08-03 2023-02-09 Summation Bio, Inc. Scaffold matrix attachment regions for gene therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
WO1996040958A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
WO1996041606A2 (en) * 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
AU1029099A (en) * 1997-10-10 1999-05-03 Aventis Pharma Deutschland Gmbh Transfection system for the transfer of nucleic acids into cells
KR20040011480A (ko) * 2001-03-22 2004-02-05 덴드레온 샌 디에고 엘엘씨 세린 프로테아제 ｃｖｓｐ14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
DK1594973T3 (da) * 2003-02-10 2012-02-13 Max Delbrueck Centrum Transposonbaseret målretningssystem
JP4521519B2 (ja) * 2003-05-26 2010-08-11 学校法人慶應義塾 部分ヒストンテイル型イムノポーター
CA2528830A1 (en) * 2003-06-10 2004-12-16 Toolgen, Inc. Transducible dna-binding proteins
US7205387B2 (en) * 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
US9746475B2 (en) * 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
US10407469B2 (en) * 2016-04-01 2019-09-10 Northwestern University Programmable polypeptide and nucleic acid nanoparticles
AU2017378427A1 (en) * 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery

Also Published As

Publication number Publication date
SG11202104354TA (en) 2021-05-28
BR112021008832A2 (pt) 2021-08-31
JP2022512977A (ja) 2022-02-07
WO2020097235A1 (en) 2020-05-14
CA3118146A1 (en) 2020-05-14
KR20210108952A (ko) 2021-09-03
IL282982A (en) 2021-06-30
CN113423834A (zh) 2021-09-21
US20210395303A1 (en) 2021-12-23
EP3877526A1 (en) 2021-09-15
AU2019376641A1 (en) 2021-05-27
JP2024029097A (ja) 2024-03-05
EP3877526A4 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
MX2021005313A (es) Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico.
MX2023003255A (es) Polipeptidos efectores crispr-cas y metodos para su uso.
MX2020004578A (es) Composiciones de casz y metodos de uso.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2020123887A3 (en) Novel crispr-cas systems for genome editing
PH12021550843A1 (en) Nucleic acid constructs and methods of use
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
WO2018160754A3 (en) Inducible monovalent antigen binding protein
BR112019023856A2 (pt) proteínas triespecíficas que visam msln e métodos de utilização
MX2021015182A (es) Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso.
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
BR112022009670A2 (pt) Polipeptídeos efetores de crispr-cas e métodos de uso dos mesmos
MX2017005199A (es) Conjugados y reactivos de conjugacion.
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
WO2017083729A3 (en) Fixatives and methods of use
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
WO2017123758A8 (en) Compositions and methods for sequencing nucleic acids
WO2016130628A8 (en) Griffithsin mutants
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
PH12021550256A1 (en) Novel crispr-associated protein and use thereof